Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma.
暂无分享,去创建一个
T. Pawlik | I. Popescu | G. Poultsides | Y. Lv | Xufeng Zhang | F. Bagante | O. Soubrane | G. Martel | A. Guglielmi | A. Workneh | L. Aldrighetti | F. Ratti | S. Alexandrescu | H. Marques | V. Lam | Hong-Fan Ding | Tom Hugh | Vincent Lam
[1] I. Endo,et al. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria , 2020, Annals of Surgical Oncology.
[2] [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]. , 2020 .
[3] A. Villanueva,et al. Biomarkers for Hepatobiliary Cancers , 2020, Hepatology.
[4] Francesca Ratti,et al. Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines , 2019, Annals of Surgical Oncology.
[5] Sheng-Nan Lu,et al. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy , 2019, Journal of clinical medicine.
[6] I. Endo,et al. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification , 2019, Annals of Surgical Oncology.
[7] A. Villanueva. Hepatocellular Carcinoma. , 2019, The New England journal of medicine.
[8] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[9] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[10] Yaming Li,et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) , 2018, Liver Cancer.
[11] K. Nan,et al. Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages , 2017, Cancer management and research.
[12] F. Roudot-thoraval,et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. , 2017, Journal of hepatology.
[13] J. H. Kim,et al. Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B , 2016, PloS one.
[14] H. Eguchi,et al. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. , 2016, Surgery.
[15] M. Schwartz,et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. , 2015, Annals of surgery.
[16] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[17] G. Spolverato,et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. , 2015, Journal of hepatology.
[18] H. Schulze‐Bergkamen,et al. Survival analysis of proposed BCLC‐B subgroups in hepatocellular carcinoma patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[19] Y. Imai,et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.
[20] S. Fan,et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. , 2014, Gastroenterology.
[21] V. Mazzaferro,et al. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions , 2012, Seminars in Liver Disease.
[22] F. Roudot-thoraval,et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. , 2012, Gastroenterology.
[23] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[24] G. Torzilli,et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. , 2008, Archives of surgery.
[25] Joris R Delanghe,et al. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[26] Sheng-Nan Lu,et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. , 2008, European journal of cancer.
[27] J. Marrero. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? , 2006, Journal of hepatology.
[28] Alessandro Vitale,et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.
[29] J. Marrero,et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.
[30] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.
[31] A. Gardini,et al. Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence , 2003, Annals of surgery.
[32] A. Befeler,et al. Hepatocellular carcinoma: diagnosis and treatment. , 2002, Gastroenterology.
[33] J. Bruix,et al. Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.
[34] M. Kojiro,et al. Immunohistologic study on the expressions of α‐fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma , 2001, Hepatology.
[35] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[36] Alessandro Vitale,et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? , 2004, Journal of hepatology.